Mesothelioma Cancer Centers
Located in New Haven, Connecticut, Yale Cancer Center is a collaborative effort between two highly respected organizations: the Yale School of Medicine, a well-known medical school and Smilow Cancer Hospital at Yale-New Haven.
It’s impossible to think about cancer treatment today without touching on a treatment that was pioneered at Yale University, namely, chemotherapy. Cancer chemotherapy and cancer drug development was discovered at Yale, and the first-ever cancer drug was administered there in 1942. The university has also played a role in other cancer milestones. As far back as the early 1900s, a Yale doctor developed a method for growing tumor cells, an important step in understanding how tumors develop. Later, the first FDA-approved selective immunotherapy treatment for cancer was developed at the university.
Over the past four decades, the center has grown into a powerhouse for research, technology and clinical care.Its successes are rooted in research. By emphasizing the molecular origins of cancer, the Yale Cancer Center promotes treatments that are created for specific types of cancers. Through this process, which the center calls “personalized medicine,” the patient can expect more targeted treatments and fewer side effects. In recent years, Yale Cancer Center has seen its facilities brought up to par with its reputation. In 2009, Yale-New Haven Hospital opened a 14-story, state-of-the-art facility specifically designed for the delivery of cancer treatment.
In terms of the treatment of mesothelioma, Yale understands and supports the common treatments of surgery, radiation therapy and chemotherapy. They strive to use a multidisciplinary approach with a team of medical oncologists, radiation oncologists and surgeons. They also support the use of clinical trials if it's in the best interest of the patient and their particular case.
- Multimodal treatment
- Clinical trials
- Mesothelioma and other asbestos-related conditions
- Connecticut Magazine Best Doctors recognition
Mesothelioma Clinical Trials at Yale Cancer Center
The following clinical trials are in progress or actively recruiting participants at Yale Cancer Center:
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma Last Updated: June 14, 2019 Status: Recruiting
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Conditions: Advanced Solid Tumors Cancer Last Updated: June 6, 2019 Status: Recruiting
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Conditions: Mesothelioma Last Updated: April 26, 2019 Status: Active, not recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
Yale Medicine. Mesothelioma: Symptoms, Diagnosis and Treatment.